\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes Digital EuropeThe European Commission has launched a 12-week open stakeholder consultation on the Digital Europe programme.
The consultation seeks to gain insights into the needs of stakeholders in the digital transformation, the perceived benefits of Digital Europe Programme, and how the programme could be improved.
The consultation targets a broad stakeholder group such as SMEs, academia, social partners, public authorities, and other public and private organisations, NGOs, and citizens from EU Member States and countries associated to the programme.
The feedback received will inform reflections on the potential for simplification and burden reduction within the Digital Europe Programme, as well as help guide the design of future initiatives. It will feed into the mid-term evaluation of Digital Europe.
For more information and to take part in the consultation please visit the consultation page.
The questionnaire is available in English, French and German, contributions are welcomed in any official EU language. Please navigate to “Respond to the questionnaire” to take part.
Deadline to respond to the consultation is 20 September 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
